TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor for the treatment of drug-resistant, relapsed, or refractory cancers. It also develops a pipeline of clinical stage product candidates and a preclinical stage product candidate. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Wu, Frank Yongqian

Employees

121

Website

www.transtherabio.com

IPO Date

2025-06-23

Headquarters

Building 9, Accelerator Phase 2, 3rd Floor, Biotech and Pharmaceutical Valley, Jiangbei New Area, Nanjing, Jiangsu Province, 210032, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

TransThera Sciences (Nanjing) 2617

TransThera Sciences (Nanjing) Earnings Call Summary

TransThera Sciences (Nanjing) Earnings

Transcripts

Events

About TransThera Sciences (Nanjing), Inc.

TransThera Sciences (Nanjing)
2617